Research & Development
Parkinson's: Page 2
Alpha-synuclein saliva biomarker for Parkinson's not ready for prime time
Researchers at the University of Athens evaluated the use of salivary α-Syn as a diagnostic marker in eight trials including a total of 1,240 patients identified through a systematic review of 476 studies. They found different results depending on the way α-Syn was measured -- total α-Syn versus oligomeric salivary α-Syn.
August 18, 2019
Parkinson's Foundation kicks off genetic testing program
The program -- dubbed PD GENEration -- will kick off at Columbia University Irving Medical Center, but other pilot sites will come on board later. Results will be stored and used for research purposes. The plan is to initially offer the testing program to 600 participants, and later roll it out to U.S. 50 centers by 2020; the foundation's long-term aim is to include 15,000 Parkinson's patients.
July 15, 2019
Cerebrospinal fluid test helps pinpoint dementia disorders
The meta-analysis of studies involving about 10,000 people with neurological disorders showed that neurofilament light protein as measured with a commercially available immunoassay was elevated for people with neurological and psychiatric conditions. Results were broadly similar; however, frontotemporal dementia and HIV-related cognitive decline were differentiated from other dementias, and Parkinson's disease was differentiated from atypical parkinsonian conditions.
June 17, 2019
Page 2 of 2